ACHV Achieve Life Sciences Inc.

$ACHV The weakness is a mystery. Story is derisked, looks like a clear path to approval and launch. I'm not selling until next year. I think we'll have a stock trading in the teen's.

$ACHV We’re now into Q4, should be getting notification of resubmission in the next “few” weeks. Slowly but surely!

$ACHV Been in and out of this name for 6 months...solid story. So we just broke the 50 day moving average and I do see that the short side is again active. Can they push it down close to the 200 day...$5.50? I'm looking to accumulate again.

$ACHV vaping news. Speeding up approvals may level the playing field for smaller companies waiting on approval. Hopefully they see the need for Achv and speed up the upcoming NDA approval once submitted to coincide with these new products. Preserving consumer choice with effective nicotine cessation for those who need it seems like a good cohesive regulatory approach. https://www.reuters.com/legal/litigation/us-fda-plans-move-speed-up-vape-pouch-approvals-wsj-reports-2026-09-23/

$ACHV On October 21, 2026, Achieve Life Sciences presented new 52-week efficacy and safety data for cytisinicline from its open-label ORCA-OL clinical trial at the CHEST 2026 Annual Meeting. The trial evaluated adults who had continued smoking or vaping daily despite prior participation in earlier short-term cytisinicline clinical trials (such as ORCA-2, ORCA-3, or ORCA-1). Participants received 3 mg of cytisinicline three times daily along with behavioral support for up to 52 weeks to study the effects of continuous, long-term exposure and retreatment.

$ACHV 🏥 Achieve Life Sciences, Inc. presented 52-week ORCA-OL results showing 39% of participants new to cytisinicline had quit smoking or vaping at one year. Market-relevant event

$ACHV Lots of tickers down heavy today. XBI down nearly 5%. This dip is more related to overall market sentiment than anything related to ACHV explicitly.

$ACHV don’t think all the younger vapers think they have a problem yet- they think they’re doing the healthier thing by not smoking- for older smokers, who have been smoking for decades, the best quit rate on the first attempt using achieve drug is still only 32%. Will play a bump in share price around the re submission of NDA by end of year tho. Plus having heavy hitters from VRNA now in key leadership positions gives me hope. Just don’t see nicotine addiction going away. Still a decent catalyst play for now

$ACHV lots of onboarding with shares for c-suite while we're far away from approval. With vaping an even longer way out, anything over half a billion is awfully rich unless something materially happens on the vaping front to speed up that timeline.